Is Semaglutide Better Than Liraglutide for Weight Loss?

The biggest misconception: they do the same job, just with different brand names

A lot of people arrive at this question assuming semaglutide and liraglutide are interchangeable, the same basic drug, different labels. They're not. Both activate the GLP-1 receptor, which is involved in appetite regulation and slowing gastric emptying. But the molecules are structurally distinct, and those differences show up in the trial results in ways that matter clinically.

Liraglutide (Saxenda, 3mg) requires a daily injection. Semaglutide (Wegovy) is once weekly. That alone changes the practical experience significantly, daily injections are a real commitment, and adherence tends to fall over time when the routine is demanding. There is also a meaningful gap in how much weight each medicine shifts on average. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average body-weight reduction with semaglutide 2.4mg at 68 weeks. The equivalent figure for liraglutide 3mg in its own pivotal trial sits closer to 8%.

So the misconception is: they're equivalent, just priced differently. The reality is that semaglutide tends to produce meaningfully greater weight loss and needs far fewer injections, as our semaglutide versus liraglutide page explores in detail. That said, individual response varies, and neither medicine works without a clinical assessment first. Which suits your situation is a question for a prescriber, not a comparison article.

What the head-to-head data actually says, and what it doesn't

There is no large-scale, long-duration randomised controlled trial directly pitting semaglutide against liraglutide head-to-head for weight loss in the same group of participants. The comparison we have is largely drawn from separate trials with different populations and designs, so the numbers are illustrative rather than definitive. With that caveat clearly stated: the gap is consistent across analyses, and NICE's appraisal of semaglutide (TA875) notes that semaglutide compares favourably with liraglutide in indirect comparisons.

The table below summarises the key factual differences. Any weight-loss figures are trial averages and do not predict individual outcomes.

For a fuller look at how semaglutide compares with other medicines in this class, the liraglutide vs semaglutide page covers the pharmacology in more depth.

What's actually licensed for weight loss in the UK right now

This matters practically. Both semaglutide and liraglutide hold UK licences for weight management. Liraglutide is not, however, a medicine that all private services stock, and it carries no NICE technology appraisal recommending it for NHS use in weight management. Semaglutide, by contrast, was appraised by NICE and recommended under TA875, albeit through specialist weight management services and for a maximum of two years.

A third option has entered the picture that is worth knowing about. Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist (the only one of its kind licensed in the UK) and in the SURMOUNT-5 trial it produced greater average weight reduction than semaglutide 2.4mg head-to-head over 72 weeks. Researchers are also watching newer agents in this space closely, and our page on whether retatrutide is better than semaglutide covers what the emerging evidence suggests. If you're weighing up options and want to understand whether Wegovy is better than semaglutide for your circumstances, the Wegovy overview is a useful place to read further.

At nume, our prescribers work with Wegovy and Mounjaro. Neither is available here without a full clinical consultation, these are prescription-only medicines, and a prescriber assesses your health history, current medicines and BMI before any treatment is considered. Which one, if either, is appropriate for you is a clinical decision, not something a comparison table can answer. Our clinical team is there to work through that with you.

Side effects and suitability: what's similar, what's different

The side-effect profiles of semaglutide and liraglutide overlap considerably, which makes sense given that both act on the GLP-1 receptor. Nausea is the most reported complaint with both, typically most noticeable when starting or after a dose increase, and it usually settles within a week or two for most people. Vomiting, loose stools, constipation, indigestion and fatigue also appear in both medicines' data.

The NHS medicines information for semaglutide is a reliable patient-level reference; the NHS semaglutide page covers what to expect and when to get medical help. Pancreatitis is a known but uncommon risk with GLP-1 medicines generally: severe, persistent stomach pain that radiates to the back is a reason to seek urgent medical attention, not to wait and see. Anyone who thinks they may be experiencing a side effect they weren't expecting can report it at yellowcard.mhra.gov.uk, the MHRA's Yellow Card scheme covers both medicines.

Suitability for either medicine depends on a full clinical picture. Pregnancy, breastfeeding, or planning to conceive are situations where neither is recommended. The same applies to anyone under 18. History of certain conditions, including pancreatitis or medullary thyroid carcinoma, requires careful prescriber discussion before any GLP-1 medicine is considered. These are the kinds of details a consultation surfaces, which is exactly why there is no shortcut around it.

If you'd like to explore what's available through a regulated UK service, you can speak to our prescribers through a free consultation. A question our team often hears is whether semaglutide is better than Ozempic, and the answer is worth understanding before you book; liraglutide is not dispensed here, but our team can discuss whether Wegovy or Mounjaro suits your situation.